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Abstract
Renal transplant recipients are at significantly greater risk of developing skin malignancies due to
combination immunosuppressive therapy. A significant number of patients present with lesions
needing excision at multiple outpatient follow-up visits. For basal cell carcinoma, we have recently
described how combining CO2 laser with Photodynamic therapy greatly increases the efficacy of
long-term tumour clearance compared with each modality alone. We present a case of a 66-year-old
renal transplant therapy patient who repeatedly presents with new skin malignancies, in whom we
treated successfully with Laser-Photodynamic therapy in a see-and-treat setting. This therapy offers
patients the possibility of better cosmetic and functional results whilst obviating the need for
repeated surgery. Other pre-cancerous lesions such as solar keratoses are prevalent in this patient
group and respond extremely well to Photodynamic therapy monotherapy. We propose a regular
clinic for renal transplant patients in a laser facility equipped with CO2 laser and Photodynamic
therapy, histopathology and punch-biopsy materials. This strategy allows simple and effective
treatment of multiple lesions simultaneously, avoidance of numerous operations, avoidance of non-
essential outpatient appointments that result in booking furthers visits for treatment, whilst
facilitating diagnostic biopsies of potentially malignant lesions. We outline a care pathway for a see-
and-treat clinic that implements this novel treatment modality improving the care of this unique
patient population.
Introduction
Basal cell carcinoma (BCC) is the most common cancer
in many parts of the world, and is increasing in incidence
in the UK [1]. Renal transplant recipients are at signifi-
cantly greater risk of developing skin malignancies due to
combination immunosuppressive therapy [2]. Surveil-
lance in these renal transplant patients for BCC and
other skin malignancies is important [3]. The morbidity
associated with BCCs is related to local tissue invasion and
destruction as well as aesthetic deformity due to both the
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disease itself and the consequences of treatment. Treat-
ment usually necessitates excision of these lesions with an
appropriate margin guided by published recommen-
dations [4], often resulting in less than ideal cosmetic
outcomes especially if local flaps or skin grafts are required
for reconstruction. Furthermore, in certain anatomical
areas such as around the eyelids, direct closure after
excision of these lesions is often precluded due to the
potential distortion of important landmarks leading to
complications such as ectropion or epiphora. Many other
treatment options exist for BCC. Topical pharmacological
therapy, cryotherapy, radiotherapy, PDT and laser have all
been used [5,6]. Non-surgical treatments remain common
and many are managed in a dermatology setting.
Photodynamic therapy (PDT) and carbon dioxide laser,
when used as monotherapy, have been successfully used
to treat both malignant and non-malignant cutaneous
lesions, including basal cell carcinoma [7] with the greatest
success in the superficial histological subtype of basal cell
carcinoma, and those of the nodular variety that are small
in size. Other pre-cancerous lesions such as solar keratoses
are prevalent in this patient group and respond extremely
well to Photodynamic therapy monotherapy [8]. These
modalities when used alone have a number of limitations
when compared to surgical excision, including a limited
depth of penetration of PDT (2 mm absorption), which
potentially limits the efficacy of treatment for nodular
BCCs greater than this thickness, or which are deeply
invasive. We have shown great success through combining
these modalities by the initial use of the CO2 laser to
debulk lesions so as to enable subsequent PDT to be
effective on any residual tumour [7]. The use of this new
strategy opens up new possibilities in the treatment of
basal cell carcinomata both clinically and logistically. To
date, we have treated almost one hundred patients without
recurrence, with follow-up times of up to three years.
Many of our patients who are renal transplant recipients
develop skin tumours requiring treatment at almost every
follow-up visit.
Case presentation
A 66-year-old British Caucasian man was referred to our
laser clinic for treatment of multiple skin malignancies, as
a result of his renal transplant therapy. He was originally
diagnosed with polycystic kidney disease at the age of 36,
and went on to undergo regular renal dialysis, until a
kidney transplant was carried out in March 1999. His other
co-morbidities include angina, hypertension and hyper-
cholesterolaemia. He has been taking cyclosporine 75 mg
BD for the past 10 years following his transplant. He has
had multiple skin lesions develop over this time, treated
by a multidisciplinary team including his GP, dermatol-
ogist and more recently by the plastic surgeons. Around
40 lesions have been treated with cryotherapy, and
12 lesions surgically excised. He was referred to our laser
clinic with 5 separate skin lesions on his back, clinically
diagnosed as BCC. After careful discussion and consent
from the patient, we decided upon combined laser and
PDT for treatment of this gentleman’s skin malignancies.
Combined laser and PDT method
We use an Ultra Pulse® CO2 Laser set at 150 mJ, 10 Hz,
with a 2 mm collimated beam to vaporise BCCs of the
nodular variety, whilst maintaining a bloodless field with
no eschar. PDT is then carried out using the photosensitiz-
ing agent Methyl Aminolevulinate (METVIX®) and illumi-
nated with the Aktilite 16 LED lamp at 631 nm, 37 J/cm2
for 7 minutes 24 seconds. In our unit we have treated
90 patients over a 3-year period with no recurrences using
this technique. Figure 1 illustrates our patient, who we
treated successfully with laser-PDT in a see-and-treat
setting. Although there is no evidence of recurrence of
previously treated lesions after 3 years follow-up, he
continues to present with new lesions elsewhere.
Our strategy for the management of this group of patients
is as follows: Basal cell carcinomas are treated with
Figure 1. Laser-PDT treatment of 5 simultaneous lesions on
a renal transplant recipient’s back, showing results 3 years
post treatment, with no sign of recurrence.
Page 2 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:7920 http://casesjournal.com/casesjournal/article/view/7920
combination laser-PDT, and biopsies undertaken simulta-
neously when necessary. Actinic keratoses (solar keratoses -
SKs) are treated with PDT alone, unless they are very
keratotic (shaved or CO2 lasered) or suspicion exists that
they are well differentiated SCCs at which time a biopsy is
undertaken. Biopsy confirmed SCCs are treated with wide
local excision, as are recurrent lesions that have previously
been treated by any modality.
The incidence of squamous cell carcinoma, in immuno-
compromised renal transplant recipients is considerably
higher compared with the normal population (up to
100-fold), and in contrast to the normal population, are
more prominent than BCCs [9]. SCC growth in transplant
patients is usually more rapid and aggressive and if there is
marked local tissue invasion and regional lymph node
metastasis, can prove life threatening. Treatment is often
difficult and recurrence common, therefore laser-PDT
therapy is not recommended in these patients, and all
SCC should be treated with wide local surgical excision.
Discussion
One may argue that surgical excision of basal cell
carcinomata is undertaken too frequently with sub-
optimal cosmetic and functional results. An elliptical
excision of a well circumscribed basal cell carcinoma with
the recommended 4 mm margin results in a substantial
defect which, even when closed directly without resorting
to a skin graft or local flap reconstruction, leads to a
significant scar much larger than the original lesion.
Furthermore, the benefit of histological confirmation of
diagnosis or clearance should not be given undue weight:
histological confirmation of tumour clearance is unavail-
able for many widely accepted methods of treatment,
particularly prevalent in the dermatology setting, and
basal cell carcinomata almost never metastasize [10] or
threaten life. One must therefore ask the question as to
whether this additional information warrants a cosmeti-
cally suboptimal surgical treatment, especially in cosme-
tically sensitive areas such as on the face. This is
particularly pertinent as studies have shown that poor
cosmesis has the most significant negative impact on the
quality of life of these patients [11]. The disadvantages of
surgical excision are compounded for renal transplant
patients in whom these lesions are numerous and
frequently occurring, making a routine surgical strategy
even less ideal.
Many problematic lesions in renal transplant patients are
solar keratoses or Bowen’s disease. PDT with or without
laser is already recognised as one of the best modalities for
treatment of these lesions [12], especially in this patient
group [13]. Tantalisingly, evidence is emerging that
treating at-risk areas of skin with PDT can prevent the
emergence of non-melanoma skin cancers [10]. This
suggests that a Laser-PDT strategy may also reduce the
incidence of other lesions in adjacent areas where
treatment has been undertaken.
Conclusion
A regular see-and-treat Laser-PDT equipped clinic provides
holistic care for patients with numerous non-melanoma
skin cancers providing a surveillance and treatment service
and providing treatments with better cosmetic outcomes
and with low recurrence rates.
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